94 related articles for article (PubMed ID: 9570976)
1. Decline in incidence of endometrial cancer following increase in prescriptions for opposed conjugated estrogens in a prepaid health plan.
Ziel HK; Finkle WD; Greenland S
Gynecol Oncol; 1998 Mar; 68(3):253-5. PubMed ID: 9570976
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of endometrial carcinoma in postmenopause].
Escudero Fernández M
Rev Med Univ Navarra; 1993; 38(3):9-12. PubMed ID: 8134756
[No Abstract] [Full Text] [Related]
4. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
5. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens.
Shapiro S; Kelly JP; Rosenberg L; Kaufman DW; Helmrich SP; Rosenshein NB; Lewis JL; Knapp RC; Stolley PD; Schottenfeld D
N Engl J Med; 1985 Oct; 313(16):969-72. PubMed ID: 2995807
[TBL] [Abstract][Full Text] [Related]
6. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium.
Shapiro S; Kaufman DW; Slone D; Rosenberg L; Miettinen OS; Stolley PD; Rosenshein NB; Watring WG; Leavitt T; Knapp RC
N Engl J Med; 1980 Aug; 303(9):485-9. PubMed ID: 6248785
[TBL] [Abstract][Full Text] [Related]
7. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype.
McCullough ML; Patel AV; Patel R; Rodriguez C; Feigelson HS; Bandera EV; Gansler T; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):73-9. PubMed ID: 18187388
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of endometrial carcinoma among users of conjugated estrogens.
Ziel HK; Finkle WD
N Engl J Med; 1975 Dec; 293(23):1167-70. PubMed ID: 171569
[TBL] [Abstract][Full Text] [Related]
9. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration.
Stefanick ML
Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329
[TBL] [Abstract][Full Text] [Related]
10. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
[TBL] [Abstract][Full Text] [Related]
11. [Estrogens and progestins in hormone replacement therapy in menopause].
La Vecchia C
Recenti Prog Med; 2001 Mar; 92(3):209-12. PubMed ID: 11320854
[TBL] [Abstract][Full Text] [Related]
12. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors.
Shields TS; Weiss NS; Voigt LF; Beresford SA
Epidemiology; 1999 Nov; 10(6):733-8. PubMed ID: 10535788
[TBL] [Abstract][Full Text] [Related]
13. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
[TBL] [Abstract][Full Text] [Related]
14. Progestins initiate adverse events of menopausal estrogen therapy.
Thomas T; Rhodin J; Clark L; Garces A
Climacteric; 2003 Dec; 6(4):293-301. PubMed ID: 15011717
[TBL] [Abstract][Full Text] [Related]
15. Replacement estrogens and endometrial cancer.
Jick H; Watkins RN; Hunter JR; Dinan BJ; Madsen S; Rothman KJ; Walker AM
N Engl J Med; 1979 Feb; 300(5):218-22. PubMed ID: 759868
[TBL] [Abstract][Full Text] [Related]
16. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation.
Reuben DB; Palla SL; Hu P; Reboussin BA; Crandall C; Herrington DM; Barrett-Connor E; Greendale GA
Am J Med; 2006 Feb; 119(2):167.e1-8. PubMed ID: 16443423
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
18. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and efficacy of different estrogens are not equivalent.
Ansbacher R
Am J Obstet Gynecol; 2001 Feb; 184(3):255-63. PubMed ID: 11228470
[TBL] [Abstract][Full Text] [Related]
20. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
Reed SD; Voigt LF; Beresford SA; Hill DA; Doherty JA; Weiss NS
Am J Obstet Gynecol; 2004 Oct; 191(4):1146-51. PubMed ID: 15507934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
